Health ❯ Healthcare ❯ Biotechnology

Clinical Trials

Drug Development Duchenne Muscular Dystrophy Autoimmune Diseases Cancer Treatment Immunotherapy Cancer Therapy Frontotemporal Dementia Antisense Oligonucleotides Rare Diseases Metabolic Diseases AI in Medicine Pulmonary Sarcoidosis Drug Efficacy Pediatric Medicine Alzheimer's Disease Nanobodies Phase 1 Studies Macrophage Therapy Eosinophilic Esophagitis Obesity Treatments Cancer Research Gene Therapy

Eupraxia Reports Early EoE Trial Data With Near‑Normal Tissue at Top Dose

Open‑label Phase 1b/2a findings are guiding a randomized Phase 2b now enrolling that is slated to deliver top‑line data in Q3 2026.

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

JPMorgan Upgrades Recursion, Raises Target to $11 as Shares Surge on AI Drug Signals

MoonLake Faces Expanding Securities Suits as Lead-Plaintiff Deadline Nears

Enlivex Raises $212 Million to Build RAIN Token Treasury, Plans Matteo Renzi Board Appointment

Protara Reports Strong Interim Phase 2 Results for TARA-002 in Pediatric Lymphatic Malformations

MoonLake Investors Courted for Lead Role in SDNY Securities Case After SLK Trial Collapse

Alector Ends Latozinemab After Phase 3 Failure, Slashes Workforce

FDA Opens Door to Reconsider Capricor’s Duchenne Cell Therapy Based on HOPE-3 Data

AbbVie Extends Rinvoq U.S. Exclusivity to 2037 as AI Biotechs Move From Models to Medicines

ATyr’s Sarcoidosis Drug Fails Phase 3 Goal, Shares Plunge Over 80%